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Abstract
Objectives: To evaluate the diagnostic accuracy of C1q autoantibodies in identifying lupus nephritis (LN) in
patients with systemic lupus erythematosus (SLE).
Data sources and methods: Citation indexes were searched and 370 articles published from 1977 to 2013 were
evaluated. The 31 selected studies included in the meta-analysis were cross-sectional in design. Among the 31
studies, 28 compared anti-C1q antibodies in 2769 SLE patients with (n=1442) and without a history of LN (n=1327).
Nine studies examined anti-C1q in 517 SLE patients with active (n=249) and inactive LN (n=268). Hierarchical
summary receiver operating characteristic (HSROC) random effects models were fitted to pool estimates of
accuracy across the studies.
Results: Anti-C1q antibodies discriminated between patients with and without a history of LN, with a median
specificity of 73.5%. The HSROC model estimated the corresponding sensitivity to be 70.4%. A hypothetical patient
with a 55% prior probability of having a history of LN as opposed to no history (the median prevalence across 28
eligible studies) would have a post-test probability of 76.4% following a positive test result (positive predictive value)
or 33.0% following a negative test result (negative predictive value). For discriminating active from inactive LN the
median specificity of anti-C1q antibodies was 80%, with a corresponding estimated sensitivity value 75.7% based on
the HSROC model. A hypothetical patient with a 56% prior probability of active as opposed to inactive LN (the
median prevalence across the 9 eligible studies) would have a post-test probability of 82.8% following a positive test
result or 27.9% following a negative test result.
Conclusions: Although C1q antibodies are associated with lupus nephritis the post-test probabilities are not
sufficiently convincing to provide reasonable certainty of the presence or absence of history of disease/active
disease.
Keywords: Autoantibody; Biopsy; Diagnosis; Enzyme-linked
immunosorbent assay (ELISA); Hierarchical summary receiver
operating characteristic (HSROC); First component of complement
(C1q); Systemic lupus erythematosus (SLE)
Introduction
The first component of complement – C1 is comprised of three
subcomponents, C1q, C1s and C1r. The C1 complex plays a pivotal
role in the activation of the classical pathway of complement. Classical
complement activation has both inflammatory and anti-inflammatory
functions. Intensive research in the 1970s afforded detailed
information on the structure and function of C1q [1]. The C1q
molecule is a 460 kDa glycoprotein with an exquisite tulip-like
structure, consisting of six globular heads each made up from three
polypeptide chains – A, B and C. Each head is attached to a central
fibril region by a triple helical collagen like tail. The C1q component of
C1 is synthesized in monocyte/macrophages and once secreted, can
bind to aggregated antibody [2] primarily on microorganisms. This
event triggers the activation of the classical complement pathway that
in turn amplifies the innate and adaptive immune responses against
infectious agents. C1q is a multi-functional protein [3], and binds to
immune complexes deposited on tissues, including the kidney [4], and
aids in their solubilization and removal [5]. C1q also plays a role in
apoptotic cell debris removal [6]. Forty years ago, the possibility of
antibodies against C1q in SLE patients was raised [7]. It was later
proposed that binding of C1q to immune complexes led to
conformational changes in the C1q structure exposing neoepitopes [8]
that may invoke an immune response. Evidence for such a response,
was demonstrated by Uwatoko et al., who observed that IgG from SLE
patient sera cross-reacted with C1q [9]. In later studies, we and others,
suggested that post-translational modifications of C1q upon exposure
to free radicals could generate antigenic neoepitopes [10-13] which
could act as a ‘trigger’, leading to the breakdown of immune tolerance
to C1q; this effect together with ‘epitope spreading’ could then
provoke the generation of antibodies to both post-translationally
modified and unmodified forms of C1q (Figure 1). The binding of
anti-C1q antibodies and other proteins to C1q is potentially of
concern as it may impede the ability of C1q to carry out its normal
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anti-inflammatory functions such as, immune complex clearance and
removal of apoptotic debris [14,15].
SLE is a multisystem autoimmune disorder with a broad spectrum
of clinical presentations. Due to the heterogeneity of the disease and
the absence of a single diagnostic test the diagnosis of SLE remains
challenging [16]. Current clinical practice requires integration of
patient’s symptoms, physical examination and diagnostic tests. Lupus
nephritis (LN), a marker of adverse outcome in SLE is common
developing in approximately 30-50% of patients overall often in the
first year after diagnosis [17]. The cumulative relapse rate for LN is in
the region of 25-40% at 5 years [18] with patients experiencing
multiple episodes of active nephritis at increased risk of progressing to
end stage renal disease [19]. Early recognition of LN is imperative to
facilitate treatment however it is clinically and histologically
heterogeneous. Diagnosis and monitoring of LN remains a
considerable clinical challenge [20,21].
Figure 1: Postulated sequence of events in the generation of anti-C1q antibodies that may act as diagnostic biomarkers of glomerulonephritis.
Nucleosome blebs from apoptotic cells can deposit on the glomerular basement membrane (GBM) in SLE patients with LN and associate with
a number of proteoglycan molecules. (A) During infection and/or inflammation anti-bacterial polysaccharide or anti-dsDNA antibodies bind
to host proteoglycans and nucleosomes, respectively. This leads to the deposition of C1 (C1q/C1r2/C1s2) on the GBM and subsequent
complement activation. (B) The release of chemotactic peptides C5a and C3a triggers the recruitment of phagocytes to the GBM in close
proximity to C1q. The activation of the phagocytes leads to the release of free radicals that can post-translationally modify (PTM) C1q. (C)
The PTM-C1q can be taken up by antigen presenting cells, and the modified peptides presented to T-cells. The autoreactive T-cells in turn
can trigger B-cell activation and ultimately the production of anti-C1q-producing plasma cells. The concentration of anti-C1q antibodies
produced in the blood can then detected by various immunoassays, including ELISA and used to assess whether a patient has or has not got
nephritis.
Many autoantibodies are prevalent in unselected SLE patients. Up
to 70% of patients have autoantibodies against single stranded-DNA
(ssDNA), 40-70% of patients have double-stranded DNA (dsDNA)
autoantibodies and around 95% of patients have anti-nuclear (ANA)
antibodies [22]. ANA and anti-ssDNA have been useful markers of
SLE disease in general, but have low specificity and are found in many
other types of musculoskeletal disorders and in infection diseases [23].
In the 1990s, a number of studies proposed that autoantibodies against
C1q in SLE patients might be pathogenic and be associated with
nephritis severity [24,25]. This led to a series of cross-sectional studies
in both Europe and the USA aimed at determining if a correlation
existed between the presence and concentration of anti-C1q antibodies
in SLE patient sera and the severity of their nephritis [26-32]. In one
early study, Siegert et al. concluded that anti-C1q autoantibodies do
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not correlate with general SLE disease activity, but found a positive
correlation between anti-C1q antibody titers and nephritis [30]. Since
then numerous other studies have assessed the usefulness of
measuring anti-C1q as a non-invasive means of detecting and
monitoring LN in SLE patients. The majority of these studies agree
that measurement of anti-C1q antibodies is a useful additional
serological marker for monitoring LN. However, due to the low
frequency of SLE in the general population, many of the single and
multicenter studies have recruited relatively small numbers of patients
between 15 and 250 individuals. Several studies have concluded anti-
C1q is not a useful marker for LN [33], others ‘slightly’ useful [34] and
others very useful for predicting renal disease [35]. This has resulted in
a lack of confidence in measuring anti-C1q in a clinical setting and to
date it is not used routinely as a diagnostic test for LN.
Given the importance of the potential association between anti-C1q
antibodies and LN, we systematically reviewed and performed a meta-
analysis of the accuracy of anti-C1q amongst SLE patients to
distinguish a) between those with and without history of LN, and b)
between those with active and inactive LN.
Studies and Methods
Identification, selection and quality assessment of studies
We searched the terms ‘nephritis’, ‘lupus’ and ‘C1q’ in the ‘any field’
bar of EndnoteX4.0.2 using several online search libraries – PubMed
(290 citations), Web of Science -TS (197 citations), National Library of
Medicine-USA (2 citations) of which 176 references were duplicates
(Figure 2). In addition, Annual Reviews, Science Direct, Medline
(EBSCO), Biomed Central, BMJ Journals, Cambridge Journals, EBSCO
EJS, Oxford Journals, Medline (Ovid), NHS Evidence, AMED
(EBSCO) and the Exeter Health Library online journal collection were
searched to ensure all relevant articles were retrieved. Four authors
(IC, AK, SM and JT) in pairs independently assessed the studies for the
accuracy of C1q autoantibodies to diagnose LN as measured by an
enzyme-linked immunosorbant assay (ELISA). We also examined the
references of all the publications we identified to ensure we had not
omitted publications other authors had identified. When data were
difficult to extract from the papers, the corresponding authors were
contacted and given the opportunity to respond.
Studies were chosen that had employed a lab-made or commercial
ELISA to screen for anti-C1q autoantibodies in 12 or more patients
per study.
QUADAS-2 (quality assessment of diagnostic accuracy studies) was
used to evaluate the risk of bias and applicability of all the studies
included in the meta-analysis [36] (http://www.bris.ac.uk/quadas/
quadas-2/). The tool assesses the quality of patient selection, the
appropriateness of the index test employed (anti-C1q ELISA), the
quality of the reference standard as the criterion for disease (lupus
nephritis) and the flow and timing of the study (time of sample
collection and analysis).
Statistical analysis
The study-specific results were extracted in the form of 2×2
contingency tables (relating the test result to disease status) for
analysis. Sensitivity and specificity estimates are reported for each
study using coupled forest plots. Sensitivity/specificity values for the
studies are also shown on summary receiver operating characteristic
(sROC) plots. Hierarchical summary receiver operating characteristic
(HSROC) random effects meta-analysis models [37] were fitted to
pool estimates of accuracy of anti-C1q for discriminating between
patients with and without history of LN and between patients with
active LN and with inactive LN. The HSROC model recognizes the
statistical heterogeneity across studies and the trade-off between
sensitivity and specificity that results from the use of different
thresholds to define a positive result on the anti-C1q test. The fitted
model defines a summary ROC curve with a specific position
(accuracy) and shape. Here we report the sensitivity value on the fitted
summary ROC curve that corresponds to the median of the specificity
values across the studies. Positive and negative likelihood ratios are
reported and in turn used to calculate post-test probabilities of
nephritis following a positive or negative anti-C1q test result for
patients with a pre-test probability of disease (or prevalence) equal to
the median percentage with nephritis across the studies. The post-test
probability of nephritis following a positive test result is the positive
predictive value and the post-test probability following a negative test
result is the complement of the negative predictive value.
Figure 2: Flow chart for the systematic selection of studies for
inclusion in the meta-analysis.
The HSROC models were fitted using a Bayesian framework in
WinBUGS software (http://www.mrc-bsu.cam.ac.uk/bugs/winbugs).
Rutter and Gatsonis [37] have described the model in detail. Uniform
priors were specified for the accuracy, threshold (representing the cut-
point on anti-C1q to indicate a positive result) and shape
(representing the degree of asymmetry of the summary ROC curve)
model parameters and inverse-gamma priors were specified for the
parameters that represent between-study variance for accuracy and
threshold. Starting values were set to zero for the accuracy and
threshold parameters and to 0.2267 for the shape parameter; to 5 for
the between-study variance components for accuracy and threshold;
and to zero for the study-specific random effects for accuracy and
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shape. For estimation, a burn-in of 10,000 iterations was used followed
by a further 100,000 iterations for the main run to monitor the
posterior distributions. Revman 5.2 software was used to produce the
couple forest plots and the summary ROC plots [38].
Results
Demographic characteristics of the patients
The meta-analysis included 31 studies in total (Table 1). Twenty
eight studies with a total of 2769 SLE patients provided data to
compare anti-C1q test result between those with (n = 1442) and
without (n=1327) a history of nephritis. Nine studies with a total of
517 SLE patients provided data to compare anti-C1q test result
between those with active (n=249) and in active LN (n=268) at the
time of blood sampling.
The ethnicities of the studies were diverse and included studies
from Europe (17/31 studies; 55%), Asia (9 studies; 29%), North and
South America (5 studies; 16%). Twenty nine of the studies assessed
anti-C1q status and LN in adults and some teenagers (age ≥ 15 years,
range 15-77), four studies focused on pediatric patients (mean age 13.9
years). Patients were recruited into the various studies with a diagnosis
of SLE ranging from 2 months to 49 years (Table 1). The percentage of
participants that was female exceeded 80% in 22 of the 24 studies that
reported these data. The majority of the studies diagnosed SLE (30/31)
using one of the American College of Rheumatology (ACR)
classifications [39,40]. A large proportion of studies (23 of 31) also
used a disease activity index to assess renal activity (Table 2), with the
SLEDAI and SLEDAI-2K being the most frequently used (21 studies).
The studies in which only ACR criteria were used tended to be the
earlier studies conducted between 1994 and 2000. Active and inactive
LN was assessed using a variety of well-established clinical parameters,
including excessive proteinuria, increase in creatinine and/or the
presence of red blood cells or cellular casts in the urine. As shown in
Table 2, there was no unified consensus how active nephritis was
monitored. The majority of the studies (28/31) used a renal biopsy as
the reference standard to diagnose active LN or historical evidence of
past episodes of nephritis, only 3 studies did not report confirmatory
biopsy for evidence of nephritis.
Reference Country & study
date
Patient Number
(samples)
% female Median/Mean Pooled
Age (range or Mean ±
SD)
Disease
duration Years
Median (range)
or mean ± SD)
Disease criteria & activity
Index
European studies
Siegert et al. [30] Netherlands
(1991)
88 91% 37 (15-73) NR ACR criteria/SLEDAI
Siegert et al. [31] Netherlands
(1993)
68 96% 38 (14-75) 6 (0.8-24) ACR criteria/ SLEDAI
Coremans et al. [27] Netherlands
(1995)
33 85% * 28.9 ± 10.2 * (3.7 ± 3.7) ACR criteria
† 34.3 ± 10.1 † (8.9 ± 6.7)
**Ravelli et al. [57] Italy
(1997)
29 90% 14.1 (7.5-19.6) (0.1-14.6) ACR criteria/ SLEDAI/SLAM
Norsworthy et al. [29] UK
(1999)
195 NR NR 0.25 – 25 BILAG
Trendelenberg et al. [58] Switzerland
(1999)
48 NR NR NR ACR criteria
Loizou et al. [59] UK
(2000)
56 95% * 31 (17-61)
§ 43 (15-74)
20-71 ACR criteria
Moroni et al. [60] Italy
(2001)
48 (61) 92% * 34 (23-43) 10.1 ACR criteria/SLEDAI
§ 38 (29-49) 11.3
Oelzner et al. [61] Germany
(2003)
79 89% 41.7 ± 13.8 0.25- 30 ACR criteria/SLEDAI
Marto et al. [62] UK
(2005)
151 93% 39 (15-74) NR ACR criteria
Sinico et al. [63] Italy
(2005)
61 NR NR NR ACR criteria/ECLAM
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Jaekell et al. [64] Germany
(2006)
100 91% 41.7 ± 13.7 NR ACR criteria/ECLAM
**Kozyro et al. [65] Switzerland
(2006)
12 50% 15 (10-17) NR ACR criteria/SLEDAI
Trendelenberg et al. [66] Switzerland
(2006)
72 NR NR NR ACR criteria
Braun et al. [67] Germany
(2007)
78 88% 37.6 ± 12.3 0.08-33.0 ACR criteria/SLEDAI
Meyer et al. [68] France
(2009)
70 91% § 30 (19-58)
§ 28 (17-48)
35 (20-76)
0.25-36
0.1-14.1
1.1-49.0
ACR criteria/SLEDAI
Smykal-Jankowiak et al.
[69]
Poland
(2011)
48 100% * 33.5 5.35 ACR criteria/SLEDAI-2K
Asian studies
Fang et al. [70] China
(2009)
180 84% * 33 ± 11.34
¶ 31.37 ± 11.70
NR ACR criteria/SLEDAI
Tan et al. [45] China
(2009)
113 NR NR NR ACR criteria/SLEDAI
Cai et al. [71] China
(2010)
73 89% ‡ 31.0 ± 13.9 ‡ (2.3 ± 1.6) ACR criteria/SLEDAI
Mok et al. [72] China
(2010)
245 95% 40.6 ± 12.2 8.7 ± 7.1 ACR criteria/SELENA-
SLEDAI
Pradhan et al. [73] India
(2010)
80 NR NR NR ACR criteria/SLEDAI
Katsumata et al. [33] Japan
(2011)
126 98% 37 (17-77) NR ACR criteria/SLEDAI-2K
**Wu et al. [74] China
(2011)
90 87% 9.8 (3-15) NR ACR criteria/SLEDAI-2K
Zhang et al. [75] China
(2011)
90 98% 37.08 ± 11.89 4.08 ACR criteria/SLEDAI
* 34.67 ± 11.21 4.74
¶ 39.95 ± 12.12 3.28
Pradhan et al. [76] India
(2012)
60 92% 29.7 (17-49) 3.6 ± 1.4 ACR criteria/SLEDAI
North/South American Studies
Bernstein et al. [26] USA
(1994)
60 NR NR NR ACR criteria
Haseley et al. [28] USA
(1997)
240 92% 41 ± 9.0 (11 ± 9.0) ACR criteria
Moura et al. [77] Brazil
(2009)
81 99% 34 ± 11 4 (0.3-32) ACR criteria/SLEDAI
De Moura et al. [78] Brazil 62 85% * 27.0 ± 5 NR ACR criteria/SLEDAI
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(2011)
† 27.5 ± 6.3
¶ 28.0 ± 8.0
**Jesus et al. [79] Brazil
(2012)
67 78% 14.6 ± 3.86 (6.4 ± 3.52) ACR criteria/SLEDAI-2K
* Active nephritis; § Inactive LN; ¶ Non-LN, active SLE with LN; †active SLE without LN; § active SLE without LN; ‡ only LN documented; bold text – median; NR: Not
Recorded; ** Pediatric study
Table 1: Summaries of demographic information of the 31studies included in the meta-analysis.
 
Reference Renal Disease Reference standards Immunoassay
used
Cut-off for +ve result
Biopsy WHO GN types I-VI Proteinuria(P)/ Creatinine
(C)
RBC count/field
Siegert et al. [30] 13/88 biopsy P>0.5 g/24 h
Increased C
>10 Lab -made >137 U/ml
Siegert et al. [31] 25/68 biopsy P>0.5 g/24 h RBCs in urine Lab-made >90 U/ml
Coremans et al. [27] 17/33 biopsy P>0.5 g/24 h >5 Lab-made >90 U/ml
**Ravelli et al. [57] 7/29 biopsy P>0.5 g/24 h
Increased C
>10 Lab-made >mean 95% OD above 59 HC
controls
Norsworthy et al. [29] 37/199 biopsy P>15 mg/ 24 h >10 Lab-made >20 U + 5 SD above controls
Trendelenberg et al.
[58]
14/48 biopsy Abnormal values of P >20 Lab-made > 80 U/ml
Loizou et al. [59] 31/56 biopsy Abnormal P NR Lab-made >20 U + 5 SD above controls
Moroni et al. [60] biopsy P>0.5 g/24 h >5 Lab-made > 80 U/ml
Oelzner et al. [61] 27/79 biopsy P ≥ 0.5 g/24 h NR IMTEC ≥ 30 U/ml
Marto et al. [62] 77/151 biopsy NR NR Diagenics >18 U/ml
Sinico et al. [63] 40/61 biopsy P>2.0 g/24 h NR Lab-made >55 U/ml
Jaekell et al. [64] Some biopsy P ≥ 0.5 g/24 h
Increased C
NR Orgentec >10 U/ml
**Kozyro et al. [65] 12/112 biopsy P>1 g/L >20 Bühlmann >15 U/ml
Trendelenberg et al.
[66]
40/72 biopsy NR >20 Bühlmann >40 U/ml
Braun et al. [67] 47/78 biopsy NR INOVA >20 U/ml
Meyer et al. [68] 55/70 biopsy P>0.5 g/dL/24 h
Increased C
Increased RBCs Bühlmann >32 U/ml
Smykal-Jankowiak et
al. [69]
37/48 Biopsy P ≥ 0.5g/24 h
serum C
Increased RBCs Bühlmann >32 U/ml
Fang et al. [70] Biopsy P>0.3 g/24 h
Increased C
≥ 5 Lab-made >mean OD + 2 SD above 63
controls
Tan et al. [45] Biopsy NR NR Lab-made >mean OD + 2 SD above 100
controls
Cai et al. [71] Biopsy P ≥ 0.5 g/24 h Increased RBCs IMTEC >20 U/ml
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Mok et al. [72] NR NR NR Euroimmun NR
Pradhan et al. [73] Biopsy NR NR Binding Site >8 U/ml
Katsumata et al. [33] 20/126 Biopsy P ≥ 0.5 g/24 h NR Bühlmann >40 U/ml
**Wu et al. [74] 28/90 Biopsy P ≥ 50 mg/Kg/24 h
Increased C
NR Lab-made >mean OD + 1 SD (40 U/ml)
above controls
Zhang et al. [75] 5/49 Biopsy P ≥ 0.5 g/24 h Increased RBCs Euroimmun ≥ 20U/ml
Pradhan et al. [76] 45/60 Biopsy NR NR Autostat II C1q-CIC ≥ 50 μg/ml anti-C1q
Bernstein et al. [26] 8/60 Biopsy P ≥ 0.5 g/24 h
Increased C
NR Lab-made >mean OD + 2 SD above 30
inactive SLE controls
Haseley et al. [28] 75/240 Biopsy P ≥ 0.5 g/24 h
Increased C
>10 Lab-made >mean OD + 5 SD above 30
controls
Moura et al. [77] No P ≥ 0.5 g/24 h
Increased C
NR INOVA >20 U/ml
De Moura et al. [78] 15/62 Biopsy P ≥ 0.5 g/24 h
serum C
NR Diagenics ≥ 20 U/L
**Jesus et al. [79] No P ≥ 0.5g/24 h
Increased C
>10 QUATA Lite >20 U/ml
** Pediatric study
OD: Optical Density; NR: Not Recorded
Table 2: Clinical assessment of nephritis and detection of anti-C1q antibodies in 31 studies.
Detection and measurement of anti-C1q antibodies by
ELISA
The studies used in this analysis all utilized at least one or more
ELISA-based immunoassays. Both lab-made and commercial anti-C1q
ELISA’s are used by various labs worldwide, and the decision to use
one type rather than another may be based on economic reasons
rather than assay precision (Table 2). Many of studies assessed both
the presence or absence of anti-C1q and the titer of C1q antibodies in
their disease cohorts. In this current investigation, we selected studies
that used ELISA-based methods so that general comparisons could be
made between studies.
One compounding observation that arose from this analysis was the
differences in the selection of a cut-off value for anti-C1q antibody
positivity (Table 2). Each study set its own criterion for ‘lab-made’
assays. Studies employing commercial assays in some instances
changed the cut-off values as recommended by the manufacturers.
 
Quality assessment
The quality of the individual studies is reported in Figure 3 for the
different criteria on the QUADAS-2 assessment tool in a format
recommended by the QUADAS-2 design team. The majority of
studies were cross-sectional in nature, recruiting unselected or
consecutive patients into their studies over a number of months or
years. Twenty-eight of the 31 studies were retrospective in nature. It
was not possible to ascertain from 30 studies whether the anti-C1q
assay was performed without any prior knowledge of the nephritis
status of the patient samples. In many routine diagnostic studies,
evaluations are frequently conducted blind to avoid bias. Only one
study claimed to use the anti-C1q ELISA diagnostically. The majority
of the studies (28/31) performed a renal biopsy in most of the patients
to confirm LN. In 24 studies, proteinuria levels were used as a means
to detect nephritis activity. Detailed analysis of raised creatinine levels
was performed in 12 studies and the frequency of red blood cells/high
powered field of view, was recorded in 16 studies (Table 2). The
majority of studies took blood samples at the time of biopsy or disease
activity assessment. The resulting isolated sera were routinely batched
stored at either -20°C or -80°C prior to being assayed for anti-C1q
autoantibodies.
The selected studies scored high for patient selection and use of
appropriate clinical assessment of nephritis. However, we identified 7
studies in which the recommended cut-off values distinguishing a
positive or negative result were not adhered too; for this reason the
studies were graded as having ‘high risk’ concerns. However, an
explanation for changing the cut-off values for the anti-C1q tests was
provided in the analyzed studies. The main reason given for adjusting
the ELISA cut-off value was to meet the needs of the individual studies
based on their own non-SLE control subject analysis. In some studies
the use of mean OD values ± 1 or more SD were used, with no
explanation as to why their results were not presented as ELISA
units/ml.
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Figure 3: QUADAS-2 quality assessment of selected studies based on inclusion rated in terms of bias and applicability.
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Figure 4: Comparing anti-C1q between patients with and without a history of lupus nephritis. (A) Coupled forest plot of sensitivity and
specificity of anti-C1q for distinguishing between patients with and without a history of LN. The sensitivity and specificity values for each
individual study are shown (squares) with 95% confidence intervals (horizontal lines). TP – true positives; FP – false positives; FN – false
negative; TN – true negatives. (B) Summary ROC plot summarizing sensitivity and specificity of anti-C1q for distinguishing between patients
with and without a history of LN. Summary ROC curve based on the fitted HSROC random effects model is shown. Each circle represents an
individual study. Points above the diagonal line indicate that the test has better classification than random assignment to a positive or negative
test result. (C) Post-test probability of LN history versus pre-test probability. Separate curves shown based on a positive anti-C1q result and a
negative anti-C1q result.
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Diagnostic ability of anti-C1q to distinguish between SLE
patients with history of LN and those without a history of LN
Twenty eight studies provided data on the accuracy of anti-C1q to
distinguish patients with a current or past history of LN from those
with no history of LN. Figure 4A shows the coupled forest plot
reporting the sensitivity and specificity estimates from the studies. The
sensitivity and specificity points are displayed in ROC space in Figure
4B, with the estimated summary ROC curve from the fitted HSROC
model drawn on the plot. The median of the specificity values at study
level was 73.5% and the estimated corresponding sensitivity estimated
by the HSROC model was 70.4% (95% Credible Interval (CrI): 57.4%
to 81.6%). The positive and negative likelihood ratios were 2.66 and
0.40, respectively. If we apply the likelihood ratio values to a
population where the underlying proportion of subjects with a history
of nephritis is 55% (the median prevalence across the 28 studies) a
positive test result would increase the probability of nephritis history
to 76.4% and a negative test result would reduce the probability to
33.3%. Figure 4C illustrates the post-test probabilities of a history of
nephritis that corresponded to different pre-test probabilities
(prevalence values), separately for those with positive and those with
negative anti-C1q test results. For a test with high predictive value the
curve for positive results would be close to the top of the graph and the
curve for negative results close to the bottom. The figure shows that
across most underlying prevalence values the anti-C1q test result does
not discriminate well and generally leaves uncertainty about the
presence of absence of a history of nephritis. In the few scenarios (pre-
test probability values above 70%) where the post-test probability of
nephritis after a positive anti-C1q result was large enough to be certain
that the condition was present the post-test probability after a negative
result was not sufficiently low to rule out the condition.
 
Diagnostic ability of anti-C1q to distinguish between SLE
patients with active LN and those with inactive LN
Nine studies provided data on the accuracy of anti-C1q for
distinguishing patients with active nephritis from those with inactive
nephritis. Figure 5A shows the coupled forest plot with sensitivity and
specificity values and Figure 5B shows the study estimates in ROC
space with the fitted curve from the HSROC model superimposed. The
median of the specificity values of the studies was 80% and the
HSROC model estimated sensitivity that corresponds to this was
75.7% (95% CrI: 46.8% to 91.3%). The positive and negative likelihood
ratios were 3.79 and 0.30, respectively. Applying these to a population
of LN subjects where the probability of active LN is 56% (the median
prevalence across the 9 studies), a positive test result would increase
the probability to 82.8% and a negative test result would reduce the
probability 27.9%. Again, the respective post-test probabilities
corresponding to the range of pre-test probability values are generally
not sufficiently extreme to ‘rule in’ active LN given a positive test result
nor rule it out given a negative test result, as illustrated in Figure 5C.
 
Discussion
There is a persisting need for lupus biomarkers that can diagnose
active organ involvement during SLE disease flares. Ahearn et al. have
recently highlighted this and the difficulties in identifying a specific
biomarker to diagnose SLE [41,42]. Among these difficulties, Ahearn
highlighted they were required to aid in a) the under- and over-
diagnosis of SLE, b) identification of lupus flares, c) stratification of
patients with various organ involvements and d) monitoring of
therapeutic interventions. To this end over 50 potential biomarkers
have been investigated for monitoring SLE [43]. Of these anti-DNA,
anti-nucleosome, monocyte chemoattractant protein-1, neutrophil
gelatinase-associated lipocalin, urinary tumor necrosis factor (TNF)-
like weak inducer of apoptosis, soluble cellular vascular adhesion
molecules, C4d levels on erythrocytes, biopsy positive C4d and anti-
C1q autoantibodies have all been investigated as renal disease
biomarkers. Of these renal biomarkers, anti-C1q has persisted over
three decades as a means of monitoring LN in SLE patents in research
studies. Autoantibodies against C1q were originally detected against
the collagen-like tail region of C1q [29,44], but more recently it has
been shown that anti-C1q antibodies are also generated against the A,
B and C chains of the globular heads of C1q [45]. Our own studies
have suggested oxidative modifications of common host proteins such
C1q may lead to breakdown of immune tolerance [46]. C1q has
abundant cysteine, methionine and phenylalanines, which are
susceptible to attack by reactive oxygen species that can lead to post-
translational modifications and possible breakdown of immune
tolerance by generating ‘foreign-appearing’ epitopes. Nitrating species
such as peroxynitrite can also modify amino acids to form stable end
products such as 3-nitrotyrosine that can be immunogenic [47]. This
may lead to the generation of unwanted anti-C1q antibodies that can
be exploited to monitor disease activity in SLE patients [48].
 
Many studies performed in the 1990s in northern Europe and the
USA assessed anti-C1q as a biomarker for detecting LN in SLE
patients. Most were enthusiastic, and whilst European centers
continue to assess anti-C1q, those in the USA appear less keen in using
anti-C1q to monitor LN. There has been a resurgence of interest in
assessing anti-C1q as a biomarker of LN in Asia and South America,
particularly in juvenile SLE patients, where renal involvement is a little
more frequent than in adults [49]. In our review of 28 studies
measuring anti-C1q antibodies to detect a history of LN in SLE
patients and 9 studies in which anti-C1q measurement was used to
distinguish between active LN and inactive LN, the post-test
probabilities after a positive test result were generally too low to be
reasonably certain of the presence of the condition. Similarly the post-
test probabilities after a negative test result were generally too high to
rule out the condition with confidence. These findings apply across
most of the range of hypothetical values for the prevalence of nephritis
history/active nephritis and suggest the measurement of anti-C1q
auto-antibodies as a ‘stand–alone’ biomarker is not diagnostically
useful.
 
The sensitivity and specificity values were highly variable across the
included studies (Figures 4 and 5). There are a number of possible
reasons for this. Some of these factors were cited in a previous meta-
analysis by Yin et al. [50], and included detection methods employed
(assay errors) and ethnicity (genetic/environmental) factors. In our
analysis we included studies in which commercial and non-
commercial ELISA methods were utilized, A frequently used
commercial assay is the Bühlmann ELISA. One recent large study of
223 SLE patients monitored anti-C1q antibodies using this and
another commercial assay [51]. This individual study was not included
in our current meta-analysis, but the corresponding author provided
additional sub-cohort data (personal communication – H Julkunen) of
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their study. The sensitivity, specificity, positive predictive value, and
negative predictive value for distinguishing active lupus nephritis
versus inactive nephritis patients (n = 104) were 44%, 90%, 58% and
84% respectively. These values were similar to the values of other
studies included in our analysis. Historically, the early studies,
particularly in the 1990s had to make their own lab-based ELISAs (as
they were not available commercially). Later studies, from 2003
onwards, frequently used commercially available ELISAs, but no single
product has been adopted throughout the lupus-research community.
For an immunoassay to be useful in routine clinical practice, clinical
laboratories should adopt a single assay procedure. This is the case for
measuring autoantibodies against cyclic citrullinated proteins (anti-
CCP) as a diagnostic assay for rheumatoid arthritis in which selected
commercial ELISAs are approved by the U.S. Food and Drug
Administration (FDA).
Figure 5: Comparing anti-C1q between patients with active and inactive lupus nephritis. (A) Coupled forest plot of sensitivity and specificity
of anti-C1q for distinguishing between patients with active LN and those with inactive LN. The sensitivity and specificity values for each
individual study are shown (squares) with 95% confidence intervals (horizontal lines). TP – true positives; FP – false positives; FN – false
negative; TN – true negatives. (B) Summary ROC plot summarizing sensitivity and specificity of anti-C1q for distinguishing between patients
with active LN and those with inactive LN. Summary ROC curve based on the fitted HSROC random effects model is shown. Each circle
represents an individual study. Points above the diagonal line indicate that the test has better classification than random assignment to a
positive or negative test result. (C) Post-test probability of active nephritis versus pre-test probability. Separate curves shown based on a
positive anti-C1q result and a negative anti-C1q result.
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The inclusion of both ‘lab-made’ and commercial anti-C1q
diagnostic ELISAs in our analysis is justified since the assay has
evolved with several stringent modifications over the past 30 years. A
natural function of C1q is to bind non-specifically to immune
complexes. Consequently, using an ELISA method employing whole
purified C1q bound to a well of an ELISA plate is susceptible to
binding to immune complexes present in the test sera, as well as to
antibodies directed against C1q. In some of the earlier studies
excluded from our analysis, this problem may have led to a higher
number of false positive results. However, it was soon realized that
raising the ionic strength of the test buffer to >0.15 M prevented the
non-specific binding of immune complexes to solid-phase bound C1q
[52], but concerns have been raised that high salt buffers can also
prevent anti-C1q autoantibodies binding to C1q [53].Various other
potential problems were raised by Siegert, including sera containing
double-stranded DNA (dsDNA) that is known to bind to the collagen
region of C1q, but increasing the salt concentration of test buffer also
alleviates this problem [24]. Another concern is the specificity of the
antibodies that bind to C1q. The collagen-like region of C1q bears
some homology to type II collagen, which is also a target for
autoantibodies in many autoimmune diseases, especially SLE and
rheumatoid arthritis. However, a study showed that the autoantibodies
directed against type II collagen differed from those that bound to the
collagen-like stalks of C1q [54]. We have recently developed a more
sophisticated form of ELISA that uses unmodified C1q and post-
translationally modified forms of C1q as a target antigen for detecting
anti-C1q autoantibodies in SLE sera. This variation may prove to be a
more specific and sensitive alternative to current anti-C1q ELISA’s
[46,47].
Ten years ago Reveille indicated that the anti-DNA antibody test
remained the ‘gold standard’ immunoassay marker for disease activity
in SLE, particularly as an indicator of LN [55] with a positive
likelihood ratio of 4.41. He also suggested other tests including anti-
C1q showed promise in monitoring renal disease in SLE patients. Our
study reveals a lack of homogeneity in performing the anti-C1q assay.
Despite this, measuring anti-C1q autoantibodies may be a useful
diagnostic test for monitoring and detecting evidence of LN in SLE
patients, but not as a ‘stand-alone’ assay, but as part of a panel of
autoantibodies as has been the recommendation for many years [56].
We would advocate that the anti-C1q immunoassay requires further
refinement and development, with greater specificity and sensitivity in
gauging LN before a single assay be adopted.
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